Omega Diagnostics Group PLC Directorate Change (8687Y)
19 Enero 2022 - 1:00AM
UK Regulatory
TIDMODX
RNS Number : 8687Y
Omega Diagnostics Group PLC
19 January 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Directorate Change
Omega (AIM: ODX), the medical diagnostics company focused on
Global Health (CD4 and COVID-19) and Health and Nutrition,
announces that Colin King, Chief Executive Officer, has notified
the Board that he will step down from his position with immediate
effect. The Board would like to thank Colin for his service over
the last six and a half years and wish him well for the future.
The Board has appointed Jag Grewal to the position of Chief
Executive Officer with immediate effect. Jag has been a member of
the Omega Board since joining in June 2011 and is currently
Managing Director of the Health and Nutrition Division . He has
over 25 years' commercial experience and an extensive network in
the fields of in vitro diagnostics, life science research and drug
discovery.
Omega also announces that Bill Rhodes, Non-Executive Director,
has notified the Board that he will also step down from his role at
the end of February 2022. The Company will begin the process of
seeking suitable Non-Executive Director candidates.
Further to recent speculation, Omega can confirm that it
currently has cash balances in excess of GBP2.5m and an undrawn
overdraft facility of GBP2.0m. Thus, there is no short term need to
raise additional capital. Like all growth companies, Omega will
look to raise funds to drive growth as and when appropriate.
Simon Douglas, Chairman of the Company, said:
"On behalf of the Board I would like to thank Colin for his
contribution to the business over the last six and a half years.
Colin has been a valued leader of the Omega team and it is with
considerable regret that he has decided to step down and I would
like to wish him all the best in his future endeavours. I also
offer my thanks to Bill for his support for the Company during his
tenure as Chairman and latterly as Non-Executive Director.
"I would also like to welcome Jag into this new role and we look
forward to working together on the next phase of Omega's exciting
future."
The information communicated in this announcement is inside
information for the purposes of Article 7 of EU Regulation
596/2014.
Contacts:
Omega Diagnostics Group PLC www.omegadiagnostics.com
Simon Douglas, Chairman via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe
(ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGPUQUGUPPGMR
(END) Dow Jones Newswires
January 19, 2022 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024